gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1063Research ArticleЛЕКЦИИ И ОБЗОРЫLECTURES AND REVIEWSРоль двигательных нарушений пищевода и желудка в патогенезе гастроэзофагеальной рефлюксной болезниThe role of esophageal and stomach motility disorders in pathogenesis of gastroesophageal reflux diseaseЕвсютинаЮ. В.YevsyutinaYu. V.

Евсютина Юлия Викторовна – аспирант кафедры пропедевтики внутренних болезней

119991, Москва, ул. Погодинская, д. 1, стр. 1. 

Yevsyutina Yuliya V. — post-graduate student, Chair of internal diseases propedeutics, medical faculty

119991, Moscow, Pogodinskaya street, 1, bld 1

uselina@mail.ruТрухмановА. С.TrukhmanovA. S.

Трухманов Александр Сергеевич – доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, руководитель лаборатории функциональной диагностики гастроэнтерологических заболеваний

119991, Москва, ул. Погодинская, д. 1, стр. 1. 

Trukhmanov Alexander S. — MD, PhD, professor, of chair of propedeutics of internal diseases, head of laboratory of functional diagnostics of gastrointestinal diseases, chair of internal diseases propedeutics, medical faculty

119991, Moscow, Pogodinskaya street, 1, bld 1. 

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Министерства здравоохранения РФРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university» Ministry of Healthcare of the Russian FederationRussian Federation2015301020152551015Copyright © Евсютина Ю.В., Трухманов А.С., 20152015Евсютина Ю.В., Трухманов А.С.Yevsyutina Y.V., Trukhmanov A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1063

Цель обзора. Предоставить данные, позволяющие рассматривать двигательные нарушения пищевода и желудка как одни из основных звеньев патогенеза гастроэзофагеальной рефлюксной болезни (ГЭРБ).Основные положения. Гастроэзофагеальную рефлюксную болезнь принято относить к кислотозависимым заболеваниям, однако важную роль в ее развитии играют двигательные нарушения пищевода и желудка. У пациентов с ГЭРБ часто имеют место нарушение первичной и вторичной перистальтики пищевода, увеличение числа преходящих расслаблений нижнего пищеводного сфинктера и наличие патологических желчных рефлюксов.Заключение. Изучению гастроэзофагеальной рефлюксной болезни посвящено большое число исследований. Активно обсуждается роль двигательных нарушений пищевода и желудка в ее патогенезе, а также общность происхождения симптомов рефлюксной болезни и других функциональных заболеваний желудочно-кишечного тракта (ЖКТ), в частности функциональной диспепсии. У пациентов с двигательными нарушениями верхних отделов ЖКТ эффективно применение прокинетиков, к примеру итоприда гидрохлорида, который способен уменьшить количество преходящих расслаблений нижнего пищеводного сфинктера за счет снижения внутрижелудочного давления, активировать пропульсивную моторику желудка и устранить дуоденогастральный и дуоденогастроэзофагеальный рефлюксы.

The aim of review

The aim of review. To demonstrate that esophageal and stomach motility disorders play one of basic roles in pathogenesis of gastroesophageal reflux disease (GERD).

Key points

Key points. Gastroesophageal reflux disease is related to the group of acid-related diseases, however esophageal and stomach motility disorders play important role in its development. In patients with GERD disorders of primary and secondary peristalsis of the esophagus, increase of frequency of transient lower esophageal sphincter relaxations and pathologic bile refluxes are common.

Conclusion

Conclusion. Numerous studies are devoted to investigation of gastroesophageal reflux disease. The role of motility disorders of the esophagus and the stomach in its pathogenesis, and origin of symptoms of reflux disease and other gastro-intestinal functional diseases, in particular the functional dyspepsia is actively discussed. At upper gastro-intestinal motility disorders application of prokinetics is effective, e.g. itopride hydrochloride, that reduces frequency of transient lower esophageal sphincter relaxations due to decrease of intragastric pressure, activates propulsive stomach motility and eliminates duodenogastric and duodenogastroesophageal refluxes.

гастроэзофагеальная рефлюксная болезньдвигательные нарушенияфункциональная диспепсияжелчный рефлюкспрокинетикиgastroesophageal reflux diseasemotor disordersfunctional dyspepsiabiliary refluxprokineticsReferencesБуеверов А.О., Лапина Т.Л. Дуоденогастроэзофагеальный рефлюкс как причина рефлюкс-эзофагита. Фарматека 2006; 1:1-5.Buyeverov A.O., Lapina T.L. Duodenogastroesophageal reflux as the cause of reflux - esophagitis. Farmateka 2006; 1:1-5.Евсютина Ю.В. Клинико-морфологические характеристики гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы: Автореф … канд мед наук. М., 2015:24 с.Yevsyutina Yu.V. Clinical and morphological features of gastroesophageal reflux disease, refractory to proton pump inhibitors: Author's abstract. MD degree thesis. М., 2015:24 p.Евсютина Ю.В., Трухманов А.С. Недостаточный ответ на терапию ингибиторами протонного насоса: причины и тактика ведения пациентов. Тер арх 2015; 2:85-9.Yevsyutina Yu.V., Trukhmanov A.S. Inadequate treatment response to proton pump inhibitors: causes and treatment approach. Ter arkh 2015; 2:85-9.Ивашкин В.Т., Шептулин А.А., Лапина Л.Т. и др. Клинические рекомендации по диагностике и лечению функциональной диспепсии. М., 2013. 36 с.Ivashkin V.T., Sheptulin A.A., Lapina T.L. et al. Diagnostics and treatment of functional dyspepsia: clinical guidelines. М., 2013. 36 p.Инструкция по применению лекарственного препарата Ганатон®.Instruction leaflet for Ganaton®.Касьяненко В.И., Денисов Н.Л., Васильев Ю.В. Применение итоприда при симптомах функциональной диспепсии в России: результаты проспективного открытого многоцентрового клинического исследования IV фазы. Тер арх 2014; 8:35-41.Kasyanenko V.I., Denisov N.L., Vasil’yev Yu.V. Application of itopride at functional dyspepsia in Russia: data of IV phase prospective open multicenter clinical trial. Ter arkh 2014; 8:35-41.Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Современный алгоритм диагностики и лечения синдрома функциональной диспепсии. Мед совет 2013; 10:6- 10.Mayev I.V., Samsonov A.A., Andreyev D.N. et al. Modern algorithm of diagnostics and treatment of functional dyspepsia syndrome. Med sovet 2013; 10:6-10.Трухманов А.С., Джахая Н.Л., Кайбышева В.О., Сторонова О.А. Новые аспекты рекомендаций по лечению больных гастроэзофагеальной рефлюксной болезнью. Гастроэнтерол гепатол 2013; 1(4):1-9.Trukhmanov A.S., Dzhakhaya N.L., Kaybysheva V.O., Storonova O.A. New points on gastroesophageal reflux disease treatment recommendations. Gastroenterol gepatol 2013; 1(4):1-9.Шептулин А.А. Хронический гепатит С: патогенез, диагностика и лечение. Рос журн гастроэнтерол гепатол колопроктол 2007; 27(4):47-50.Sheptulin A.A. Chronic hepatitis C: pathogenesis, diagnostics and treatment. Ros zhurn gastroenterol gepatol koloproktol 2007; 27(4):47-50.Ang D., Sifrim D., Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008; 5:383-92. 11. Boeckxstaens G.E. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008; 8:685-9.Ang D., Sifrim D., Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008; 5:383-92. 11. Boeckxstaens G.E. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008; 8:685-9.Choung R.S., Locke G.R., Schleck C.D., Zinsmeister A.R., Talley N.J. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil 2012; 24:229-34.Choung R.S., Locke G.R., Schleck C.D., Zinsmeister A.R., Talley N.J. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil 2012; 24:229-34.El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2014; 63:871-80.El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2014; 63:871-80.Gupta S., Kapoor V., Kapoor B. Itopride: A novel prokinetic agent. Science 2004; 6(2):106-8.Gupta S., Kapoor V., Kapoor B. Itopride: A novel prokinetic agent. Science 2004; 6(2):106-8.Gwee K.A., Hwang J.E., Ho K.Y., Yeoh K.G., Lum C.F., Ang P.K. In-practice predictors of response to proton pump inhibitor therapy in primary care patients with dyspepsia in an Asian population. J Clin Gastroenterol 2008; 42:134-8.Gwee K.A., Hwang J.E., Ho K.Y., Yeoh K.G., Lum C.F., Ang P.K. In-practice predictors of response to proton pump inhibitor therapy in primary care patients with dyspepsia in an Asian population. J Clin Gastroenterol 2008; 42:134-8.Hvid-Jensen F., Pedersen L., Funch-Jensen P., Drewes A.M. Proton pump inhibitor use may not prevent high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Aliment Pharmacol Ther 2014; 39(9):984-91.Hvid-Jensen F., Pedersen L., Funch-Jensen P., Drewes A.M. Proton pump inhibitor use may not prevent high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Aliment Pharmacol Ther 2014; 39(9):984-91.Kim Y.S., et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005; 11(27):4210-4.Kim Y.S., et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005; 11(27):4210-4.Kohata Y., Fujiwara Y., Machida H., et al. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol 2012; 27(Suppl 3):58-62.Kohata Y., Fujiwara Y., Machida H., et al. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol 2012; 27(Suppl 3):58-62.Lee S.W., Chang C.S., Lien H.C., Peng Y.C., Wu C.Y., Yeh H.Z. Impact of overlapping functional gastrointestinal disorders on the presentation and quality of life of patients with erosive esophagitis and non-erosive reflux disease. Med Princ Pract 2015; 24(5):1-5.Lee S.W., Chang C.S., Lien H.C., Peng Y.C., Wu C.Y., Yeh H.Z. Impact of overlapping functional gastrointestinal disorders on the presentation and quality of life of patients with erosive esophagitis and non-erosive reflux disease. Med Princ Pract 2015; 24(5):1-5.Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil 2010; 16:148-56. 21. Ohara S., Kawano T., Kusano M., Kouzu T. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. J Gastroenterol 2011; 46:603-11.Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil 2010; 16:148-56. 21. Ohara S., Kawano T., Kusano M., Kouzu T. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. J Gastroenterol 2011; 46:603-11.Olmos J.A., Pogorelsky V., Tobal F., et al. Uninvestigated dyspepsia in Latin America: a population-based study. Dig Dis Sci 2006;51:1922-9. 23. Piessevaux H., de Winter B., Louis E., et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21:378-88.Olmos J.A., Pogorelsky V., Tobal F., et al. Uninvestigated dyspepsia in Latin America: a population-based study. Dig Dis Sci 2006;51:1922-9. 23. Piessevaux H., de Winter B., Louis E., et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21:378-88.Rasmussen S., Jensen T.H., Henriksen S.L., Haastrup P.F., Larsen P.V., Søndergaard J., Jarbøl D.E. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol 2015; 50(2):162-9. 25. Savarino E., Pohl D., Zentilin P., et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58:1185- 91.Rasmussen S., Jensen T.H., Henriksen S.L., Haastrup P.F., Larsen P.V., Søndergaard J., Jarbøl D.E. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol 2015; 50(2):162-9. 25. Savarino E., Pohl D., Zentilin P., et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58:1185- 91.Savarino V., Savarino E. Is acid relevant in the genesis of dyspeptic symptoms associated with non-erosive reflux disease? Eur J Gastroenterol Hepatol 2008; 20:252-4.Savarino V., Savarino E. Is acid relevant in the genesis of dyspeptic symptoms associated with non-erosive reflux disease? Eur J Gastroenterol Hepatol 2008; 20:252-4.Scarpellini E., Vos R., Blondeau K., et al. The effects of itopride on esophageal motility and lower esophageal sphincter function in man. Aliment Pharmacol Ther 2011;33:99-105.Scarpellini E., Vos R., Blondeau K., et al. The effects of itopride on esophageal motility and lower esophageal sphincter function in man. Aliment Pharmacol Ther 2011;33:99-105.Sifrim D., Holloway R., Silny J., Tack J., Lerut A., Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:647-55.Sifrim D., Holloway R., Silny J., Tack J., Lerut A., Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:647-55.Sifrim D., Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61:1340-54.Sifrim D., Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61:1340-54.Su Youn Nam, Kum Hei Ryu, Bum Joon Park. Irritable bowel syndrome is associated with gastroesophageal reflux symptom but not erosive esophagitis. J Neurogastroenterol Motil 2013; 19(4):521-31.Su Youn Nam, Kum Hei Ryu, Bum Joon Park. Irritable bowel syndrome is associated with gastroesophageal reflux symptom but not erosive esophagitis. J Neurogastroenterol Motil 2013; 19(4):521-31.Tack J. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and non-erosive reflux disease. Curr Opin Gastroenterol 2005; 21:454-60.Tack J. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and non-erosive reflux disease. Curr Opin Gastroenterol 2005; 21:454-60.Talley N.J., Tack J., Ptak T., et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57:740-6.Talley N.J., Tack J., Ptak T., et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57:740-6.Wang A.J., Wang H., Xu L., et al. Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease. Dig Liver Dis 2013; 45:296- 300.Wang A.J., Wang H., Xu L., et al. Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease. Dig Liver Dis 2013; 45:296- 300.Zerbib F., Belhocine K., Simon M. Clinical, but not esophageal pH-impedance, profiles predict response to proton pump inhibitors in gastroesophageal reflux disease. Gut 2012; 61:501-6.Zerbib F., Belhocine K., Simon M. Clinical, but not esophageal pH-impedance, profiles predict response to proton pump inhibitors in gastroesophageal reflux disease. Gut 2012; 61:501-6.

The authors declare that there are no conflicts of interest present.